Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Proteome Sciences plc    PRM   GB0003104196

PROTEOME SCIENCES PLC (PRM)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/15/2018 01/16/2018 01/17/2018 01/18/2018 01/19/2018 Date
3.1(c) 3.1(c) 3.1(c) 3.07(c) 3.1(c) Last
0 0 5 536 0 0 Volume
0.00% 0.00% 0.00% -0.97% +0.98% Change
More quotes
Financials ( GBP)
Sales 2017 4,10 M
EBIT 2017 -1,60 M
Net income 2017 -
Debt 2017 -
Yield 2017 -
Sales 2018 5,50 M
EBIT 2018 -0,10 M
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 31,00
Capi. / Sales2017 2,23x
Capi. / Sales2018 1,66x
Capitalization 9,15 M
More Financials
Company
Proteome Sciences Plc is engaged in applied proteomics and peptidomics services and applications.It offers proprietary technologies for protein and peptide biomarker discovery, validation, and assay development.The company focuses on developing proprietary protein biomarkers for neurological... 
More about the company
Latest news on PROTEOME SCIENCES PLC
2017 PROTEOME SCIENCES : announce Good Clinical Laboratory Practice accreditation
2017 PROTEOME SCIENCES : Interim results for the six months ended 30 June 2017
2017 PROTEOME SCIENCES : Stroke Diagnostic Presentation at EuroMedLab 2017 – Re..
2017 THERMO FISHER SCIENTIFIC : Recognizes Tandem Mass Tag Grant Award Winners at ASM..
2017 PROTEOME SCIENCES : AGM Statement and Result of AGM
2017 PROTEOME SCIENCES : Trading Remains In Line With Expectations
2017 PROTEOME SCIENCES : Appoints Richard Dennis Chief Commercial Officer
2017 PROTEOME SCIENCES : Appointment of Richard Dennis as Chief Commercial Officer
2017 PROTEOME SCIENCES : Annual Report and Accounts 2016
2017 PROTEOME SCIENCES : Says "Much Yet To Do" As Loss Narrows In 2016
More news
Sector news : Bio Therapeutic Drugs
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Bio Therapeutic Drugs
Latest Tweets
2017Proteome Sciences plc's corporate rating reiterated at FinnCap.  
2017$PRM - Martin Diggle Purchases 119,636 Shares of Proteome Sciences plc #PRM S.. 
2017Proteome Sciences plc's corporate rating reiterated at FinnCap.  
2017Proteome Sciences plc's corporate rating reiterated at FinnCap. GBX 12 PT.  
2017Proteome Sciences plc's corporate rating reiterated at FinnCap. GBX 12 PT.  
More tweets
Qtime:40
Chart PROTEOME SCIENCES PLC
Duration : Period :
Proteome Sciences plc Technical Analysis Chart | PRM | GB0003104196 | 4-Traders
Technical analysis trends PROTEOME SCIENCES PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
EPS Revisions
Managers
NameTitle
Jeremy Rupert Michael Haigh Chief Executive Officer & Executive Director
Christopher D. J. Pearce Non-Executive Chairman
Stefan Fuhrmann Finance Director
Ian H. Pike Executive Director & Chief Scientific Officer
Roger Steven McDowell Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
PROTEOME SCIENCES PLC-1.76%13
GILEAD SCIENCES14.10%105 754
VERTEX PHARMACEUTICALS4.76%39 951
REGENERON PHARMACEUTICALS-0.50%39 917
GENMAB10.50%11 762
EXELIXIS, INC.-9.57%8 284